

ASPERGILLUS GM LATERAL FLOW ASSAY

test BENEFITS

- 30 minute run time Simplified procedure
- High sensitivity and specificity
- Serum & BAL Capable
- Eliminate batch testing

the PROBLEM

Over 30 million people are at risk of invasive aspergillosis each year because of corticosteroid use or other therapies, and over 300,000 patients develop it annually.

The disease is common in high-risk patients with:

- Hematological malignancies
- Allogeneic HSCT (stem cell transplant)
- Chemotherapy-induced neutropenia
- Solid organ transplant (primarily lung)

real VALUE

- Delivers accurate results in **30 minutes**, reducing time to proper treatment for patients.
- Test at-risk patients more frequently.
- Simplified procedure with minimal specimen preparation.
- Eliminate delays in diagnosis due to batch testing.

true PERFORMANCE

The sona AGM LFA displays high performance in both specimen types:

<u>Serum</u>	Asp Ag EIA		
Asp GM LFA Assay		Pos	Neg
	Pos	26	1
	Neg	6	116


Serum	Calculated	95% CI
% Agreement Pos	81%	64% - 93%
% Agreement Neg	99%	95% - 99.9%

<u>BAL</u>	Asp Ag EIA		
Asp GM		Pos	Neg
LFA Assay	Pos	25	3
	Neg	3	48

BAL	Calculated	95% CI
% Agreement Pos	89%	72% - 98%
% Agreement Neg	94%	84% - 99%

simple PROCEDURE

AGMLFA



Please check regulatory status in your country.